Advice
Medicine withdrawn
On 31 March 2020, ombitasvir/paritaprevir/ritonavir (Viekirax) and dasabuvir (Exviera) ceased to be marketed.
Medicine details
- Medicine name:
- ombitasvir / paritaprevir ritonavir (Viekirax) and dasabuvir (Exviera)
- SMC ID:
- 1051/15
- Indication:
Ombitasvir/paritaprevir/ritonavir (Viekirax®) for use in combination with dasabuvir (Exviera®) with or without ribavirin for the treatment of genotype 1 chronic hepatitis C (CHC) in adults.
- Pharmaceutical company
- AbbVie Ltd
- BNF chapter
- Infections
- Submission type
- Full
- Status
- Withdrawn
- Date advice published
- 08 June 2015
Additional notes
On 31 March 2021, ombitasvir/paritaprevir/ritonavir (Viekirax) and dasabuvir (Exviera) ceased to be marketed.
In line with SMC process the SMC advice has been removed from the website.